- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.03. | Coeptis Therapeutics Holdings, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
| 09.03. | Coeptis Therapeutics: Vanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds Build | 1.124 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / March 9, 2026 / When Coeptis Therapeutics Holdings, Inc. (Nasdaq:COEP) and Z Squared Inc. announced their transformational merger in April 2025, the process ahead was... ► Artikel lesen | |
| 12.02. | Coeptis Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Coeptis Therapeutics: Coeptis Receives Shareholder Approval Towards Z Squared Merger | 190 | GlobeNewswire (Europe) | WEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, today announced... ► Artikel lesen | |
| 04.02. | Coeptis Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| COEPTIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.02. | Vanderbilt Report: Coeptis Therapeutics Shareholders Approve Transformational Merger: From Biopharma to Dual-Sector Platform | 570 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / February 4, 2026 / Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) shareholders approved a transformational merger that converts a clinical-stage biopharmaceutical... ► Artikel lesen | |
| 16.01. | NASDAQ rügt Coeptis Therapeutics wegen verspäteter Hauptversammlung | 1 | Investing.com Deutsch | ||
| 16.01. | Coeptis Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.01. | Coeptis Therapeutics Holdings Details $835M Transaction Structure with Z-Squared; Vanderbilt Report Publishes Coverage | 383 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / January 6, 2026 / The Vanderbilt Report today published coverage of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) following the company's recent SEC filings detailing... ► Artikel lesen | |
| 06.01. | Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared | 164 | GlobeNewswire (Europe) | WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company,, announced today... ► Artikel lesen | |
| 22.12.25 | Coeptis Therapeutics Holdings, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 10.12.25 | Coeptis Therapeutics Holdings, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 03.10.25 | Coeptis Therapeutics Holdings, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
| 01.10.25 | Coeptis Therapeutics: Coeptis Anchors $800M Valuation in Dual-Sector Strategy; Vanderbilt Report Publishes Coverage | 303 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / October 1, 2025 / Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) today announced that The Vanderbilt Report has published coverage of the company following its recent... ► Artikel lesen | |
| 25.04.25 | Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement | 341 | GlobeNewswire (Europe) | WEXFORD, Pa., April 25, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq; COEP) ("Coeptis" or the "Company"), a biopharmaceutical and technology company focused on developing innovative... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 276,44 | -4,53 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs | ||
| QIAGEN | 34,540 | 0,00 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,510 | -0,68 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer | RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities... ► Artikel lesen | |
| RELAY THERAPEUTICS | 9,350 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| BULLFROG AI | 1,070 | 0,00 % | Bullfrog AI stock offers a rare opportunity for investors to take profit | ||
| ALUMIS | 20,130 | 0,00 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,165 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ERASCA | 14,940 | 0,00 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| NUVALENT | 96,81 | +0,16 % | Wells Fargo stuft Nuvalent wegen hohem Medikamentenpotenzial mit "Overweight" ein | ||
| ARCELLX | 114,76 | +0,17 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| CG ONCOLOGY | 63,90 | -1,19 % | UBS raises CG Oncology stock price target to $90 on trial outlook | ||
| ARRIVENT BIOPHARMA | 21,010 | -1,82 % | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 36,650 | -5,78 % | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | ||
| EVOTEC | 4,270 | 0,00 % | Evotec-Aktie satt im Plus - Startschuss zur Trendwende? | Die Aktie des Hamburger Wirkstoffforschers gehört mit einem Plus von knapp sieben Prozent zur Wochenmitte zu den stärksten Werten im SDAX. Damit setzt sich der Biotech-Titel wieder deutlicher von den... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,69 | 0,00 % | BTIG reiterates Buy on Apogee Therapeutics stock, $137 target |
COEPTIS THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 10,480 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COEPTIS THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.